"Research Article"
American Journal of BioMedicine Volume 3, Issue 1, pages 22-31, January 2015
Grace Hullmann; Michael A. Azfer; Jordan Hensley; Albertine Bergese; Jack Lefer
Abstract
Interleukin-1 (IL-1) family is a critical mediator of immune response to sepsis with two agonists (IL-1α and IL-1β) and one antagonist (IL-1 receptor antagonist: IL-1ra). Excessive IL-1 production is directly linked to the development of shock, multi-organ system failure, and death in patients and animals with sepsis, systemic inflammatory response syndrome, and septic shock. Further, recent reports have indicated that IL-1[beta] is excessively released into the circulation during renal sepsis. The ojective of this study is to investigate the effective role of IL-1β in mechanism of TLR4-induces renal sepsis. LPS administration induces systemic inflammation in wild type mice that mimics many of the initial clinical features of sepsis, including increases in proinflammatory cytokines. renal function was assessed and Chemokines and cytokines in plasma and renal tissue were analyzed by enzyme-linked immunosorbent assay (ELISA). Mononuclear cells in the myocardium were examined using immunofluorescence staining.IL-1β and other proinflammatory cytokines were measured. The WT mice have enhanced inflammatory responses to sepsis that lead to exaggerated renal functional reduction. MCP-1 promotes renal mononuclear cell accumulation, These results demonstrate that IL-1β plays a detrimental role in the development of renal sepsis in this murine model, suggesting that it may be applicable to clinical situations, such as trauma, shock and renal transplantation.
Keywords: Renal sepsis; IL-1β; Cytokines; MCP-1
Limited Access Full Text-PDF Feedback
References
1. Tavener SA, Long EM, Robbins SM, et al. Immune cell Toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia.Circ Res 2004; 95:700–7. [PubMed]
2. Hamdy AA, Ebrahem MA. The effect of interleukin-1 allele 2 genotype (IL-1a(-889) and IL-1b(+3954)) on the individual's susceptibility to peri-implantitis: case-control study. J Oral Implantol 2011; 37(3):325-34. [PubMed]
3. Raeburn C, Dinarello CA, et al. Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol 2002; 283:H650–7. [PubMed]
4. Moldovan NI, Goldschmidt-Clermont PJ, Parker-Thornburg J, Shapiro SD, Kolattukudy PE. Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metal-loelastase-positive tunnels in ischemic myocardium. Circ Res 2000; 87:378-84. [PubMed]
5. Slimani H, Zhai Y, Yousif NG, et al. Enhanced monocyte chemoattractant protein-1 production in aging mice exaggerates cardiac depression during endotoxemia. Critical care 2014;18(5):527. [PubMed]
6. Pulskens WP, Rampanelli E,Teske GJ, et al. TLR4 Promotes Fibrosis but Attenuates Tubular Damage in Progressive Renal Injury. J Am Soc Nephrol 2010; 21(8):1299–1308. [PubMed]
7. Johnson GB, Brunn GJ, Platt JL. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 2003; 23:15–44. [PubMed]
8. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being viadetection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002;168: 5233–5239. [PubMed]
9. Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 370–7377. [PubMed]
10. Vabulas RM, Braedel S, Hilf N, et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem 2002; 277: 20847–20853. [PubMed]
11. Klueh U, Liu Z, Feldman B, Kreutzer D. Importance of Interleukin-1 and Interleukin-1 Receptor Antagonist in Short-Term Glucose Sensor Function in Vivo. J Diabetes Sci Technol 2010; 4(5):1073–1086. [PubMed]
12. Zhang A, Pan W, Gao J, Yue C, Zeng L, Gu W, Jian-xin Jiang. Associations between interleukin-1 gene polymorphisms and sepsis risk: a meta-analysis. BMC Med Genet 2014;15:8. [PubMed]
13. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008;15(10):776–787. [PubMed]
14. Wen AQ, Gu W, Zeng L, et al. Clinical relevance of IL-1beta promoter polymorphisms (-1470, -511, and -31) in patients with Chinese major trauma patients. Shock 2010;15(6):576–582. [PubMed]
15. Watanabe E, Buchman TG, Hirasawa H, Zehnbauer BA. Association between lymphotoxin-(alpha) (tumor necrosis factor-(beta)) intron polymorphism and predisposition to severe sepsis is modified by gender and age. Crit Care Med 2010;15(1):181–193. [PubMed]
16. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992;15(6):396–402. [PubMed]
17. Witkin SS, Gerber S, Ledger WJ. Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 2002;15(2):204–209. [PubMed]
18. Grealy R, White M, Stordeur P, Kelleher D, Doherty DG, McManus R, Ryan T. Characterising cytokine gene expression signatures in patients with severe sepsis. Mediators Inflamm 2013;15:164246. [PubMed]
19. Tang BM, Huang SJ, McLean AS. Genome-wide transcription profiling of human sepsis: a systematic review. Critical Care 2010;14(6, article R237). [PubMed]
20. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. Journal of Infectious Diseases 2000;181(1):176–180. [PubMed]
